Treatment strategy for recurrent and refractory epithelial ovarian cancer: Efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation

Acta Histochemica et Cytochemica

Volumn 39, Issue 3, 2006, Pages 61-67

  Muramatsu, Toshinari ^a   Shinozuka, Takao ^b   Hirasawa, Takeshi ^a   Tsukada, Hitomi ^a   Maeda, Hironobu ^a   Miyamoto, Tsuyoshi ^a   Murakami, Masaru ^a   Kajiwara, Hiroshi ^a   Yasuda, Masanori ^a   Osamura, R Yoshiyuki ^a   Mikami, Mikio ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Gynecology   (Japan)

Author keywords

Hematopoietic stem cell transplantation; High dose chemotherapy; Recurrent refractory ovarian cancer; Treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CROSS TOLERANCE; DEMOGRAPHY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; HOSPITAL; HUMAN; JAPAN; KIDNEY DISEASE; MORBIDITY; NEPHROTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; POPULATION; RECURRENT DISEASE; REVIEW; STEM CELL TRANSPLANTATION; VISUAL DISORDER;

EID: 33745685748     PISSN: 00445991     EISSN: 13475800     Source Type: Journal    
DOI: 10.1267/ahc.05030     Document Type: Review

References (42)

1. Aabo, K., Adams, M., Adnitt, P., Alberts, D. S., Athanazziou, A., Barley, V., Bell, D. R., Bianchi, U., Bolis, G., Brady, M. F., Brodovsky, H. S., Bruckner, H., Buyse, M., Canetta, R., Chylak, V., Cohen, C. J., Colombo, N., Conte, P. F., Crowther, D., Edmonson, J. H., Gennatas, C., Gilbey, E., Gore, M., Guthrie, D., Kaye, S. B., Laing, A. H., Landoni, F., Leonard, R. C., Lewis, C., Liu, P. Y., Mnangioni, C., Marsoni, S., Meerpohl, H., Omura, G. A., Parmar, M. K. B., Pater, J., Pecorelli, S., Presti, M., Sauerbrei, W., Skarlos, D. V., Smalley, R. V., Solomon, H. J., Stewart, L. A., Sturgeon, J. F. G., Tattersall, M. H. N., Wharton, J. T., ten Bokkel Huinink, W. W., Tomirotti, M., Torri, W., Trope, C., Tubow, M. M., Vermorken, J. B., Webb, M. J., Wilbur, D. W., Williams, C. J., Wiltshaw, E. and Yeap, B. Y. (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br. J. Cancer 78; 1479-1487.
2. Alberts, D. S., Young, L., Mason, N. and Salmon, S. E. (1985) In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin. Oncol. 12; 38-42.
3. Andrews, P. A., Velury, S., Mann, S. C. and Howell, S. B. (1988) cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant ovarian carcinoma cells. Cancer Res. 48; 68-73.
4. Balat, O., Kudelka, A. P., Tunca, J. C., Edwards, C. L., Verschraegen, C. and Kavanagh, J. J. (1996) Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report. Eur. J. Gynaecol. Oncol. 17; 264-266.
5. Broun, E. R., Belinson, J. L., Berek, J. S., Berek, J. S., McIntosh, D., Hurd, D., Ball, H. and Williams, S. (1994) Salvage therapy for recurrent or refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study. Gynecol. Oncol. 54; 142-146.
6. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E. and Wiltshaw, E. (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7; 1748-1756.
7. Conte, P. F., Bruzzone, M., Carnino, F., Chiara, S., Donadio, M., Facchini, V., Fioretti, P., Foglia, G., Gadducci, A., Gallo, L., Giaccone, G., Guercio, E., Iskra, L., Janssen, N., Maresi, M. P., Parodi, G., Ragni, N., Rosso, R., Rubagotti, A., Rugiati, S., Storace, A., Venturini, S. and Pescetto, G. (1991) Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J. Clin. Oncol. 9; 658-663.
8. Conte, P. F., Bruzzone, M., Carnino, F., Gadducci, A., Algeri, R., Bellini, A., Boccardo, F., Brunetti, I., Catsafados, E., Chiara, S., Folia, G., Gallo, L., Iskra, L., Mammoliti, S., Parodi, G., Ragni, N., Rosso, R., Rugiati, S. and Rubagotti, A. (1996) High-dose vs low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of Gruppo Oncologico Nord-Ovest. J. Clin. Oncol. 14; 351-356.
9. du Bois, A., Luck, H. J., Meier, W., Adams, H. P., Mobus, V., Costa, S., Bauknecht, T., Richter, B., Warm, M., Schroder, W., Olbricht, S., Nitz, U., Jackisch, C., Emons, G., Wagner, U., Kuhn, W. and Pfisterer, J.: Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95; 1320-1329.
10. Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowicz, C. D. and Goldberg, G. L. (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian carcinoma. J. Clin. Oncol. 10; 1748-1753.
11. Hirasawa, T., Yasuda, M., Maeda, H., Muramatsu, T., Miyamoto, T., Murakami, M., Shinozuka, T., Takekoshi, S., Osamura, R. Y. and Makino, T. (2004) Modification of p53 immunoexpression associated with chemotherapy regimens in advanced and refractory ovarian cancers. Acta Histochem. Cytochem. 37; 15-20.
12. Holmberg, L. A., Demirer, T., Rowley, S., Bucker, C. D., Goodman, G., Maziarz, R., Klarnet, J., Zuckerman, N., Harrer, G., McCloskey, R., Gersh, R., Goldberg, R., Nichols, W., Jacobs, A., Weiden, P., Montgomery, P., Rivkin, S., Appelbaum, F. R. and Bensinger, W. I. (1998) High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant. 22; 651-659.
13. Hunter, R. E., Griffin, T. W., Stevens, S., Roman, L. D., Bokhari, F., Reale, F. R., Tak, W. K., Fitzgerald, T. J., Dillon, M. B. and Rose, P. G. (1991) High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer. Cancer 68; 1890-1894.
14. Jakobsen, A., Bertelsen, K., Andersen, J. E., Havsteen, H., Jakobsen, P., Moeller, K. A., Nielsen, K., Sandberg, E. and Stroeyer, I. (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J. Clin. Oncol. 15; 193-198.
15. Kaye, S. B., Lewis, C. R., Paul, J., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Cassidy, J., Davis, J. A., Reed, N. S., Crawford, S. M., MacLean, A., Swapp, G. A., Sarkar, T. K. and Kennedy, J. H. (1992) Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340; 329-333.
16. Kaye, S. B., Paul, J., Cassidy, J., Lewis, C. R., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Davis, J. A., Reed, N. S., Crawford, S. M., MacLean, A., Parkin, D., Sarkar, T. K., Kennedy, J. and Symonds, R. P. (1996) Mature results of randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J. Clin. Oncol. 14; 2113-2119.
17. Kehoe, S., Redman, C., Varma, R., Buxton, J., Luesly, D., Blackledge, G. and Stanley, A. (1992) Single agent high-dose cisplatin (200 mg m-2) treatment in ovarian carcinoma. Br. J. Cancer 66; 717-719.
18. Ledermann, J. A., Herd, R., Maraninchi, D., Viens, P., Buclon, M., Philip, T., Cure, H., Lotz, J. P., Chauvin, F., Ferrante, P. and Rosti, G. (2001) High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann. Oncol. 12; 693-699.
19. Legros, M., Dauplat, J., Fleury, J., Cure, H., Suzanne, F., Chassagne, J., Bay, J. O., Sol, C., Canis, M., Condat, P., Choufi, B., Tavernier, F., Glenot, C., Chollet, P. and Plagne, R. (1997) High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J. Clin. Oncol. 15; 1302-1308.
20. Lewin, L., Simon, R. and Hryniuk, W. (1993) Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose-intensity analysis. J. Natl. Cancer Inst. 85; 1732-1742.
21. McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S. and Woodward, J. (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13; 1589-1599.
22. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L. and Davidson, M. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334; 1-6.
23. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L. and Davidson, M. (1997) Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin. Oncol. 24; s2-13-s2-16.
24. Miyamoto, T., Shinozuka, T., Maeda, H., Hirasawa, T., Muramatsu, T., Murakami, M., Makino, T., Itagaki, H. and Nakamura, Y. (2004) Effect of peripheral blood progenitor cell dose on hematopoietic recovery: identification of minimal progenitor cell requirements for rapid engraftment. Bone Marrow Transplant. 33; 589-595.
25. Mulder, P. O., Sleijfer, D. T., Willemse, P. H., de Vries, E. G., Uges, D. R. and Mulder, N. H. (1989) High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res. 49; 4654-4658.
26. Mulder, P. O., Willemse, P. H., Aalders, J. G., de Vries, E. G., Sleijfer, D. T., Sibinga, C. T. and Mulder, N. H. (1989) High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur. J. Cancer Clin. Oncol. 25; 645-649.
27. Murakami, M., Shinozuka, T., Miyamoto, T., Fujii, A. and Tokuda, Y. (1993) The impact of autologous bone marrow transplantation on hematopoietic recovery after high-dose cyclophosphamide, doxorubicin, and cisplatin chemotherapy for patients with gynecological malignancies. Asia Oceania J. Obstet. Gynaecol. 19; 85-93.
28. Murakami, M., Shinozuka, T., Kuroshima, Y., Tokuda, Y. and Tajima, T. (1994) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors. Semin. Oncol. 21; 29-32.
29. Muramatsu, T., Shinozuka, T., Hirasawa, T., Maeda, H., Miyamoto, T., Kuroshima, Y., Makino, T. and Tanaka, Y. (1997) A case of recurrent cervical cancer with cortical blindness after chemotherapy with Cis-platinum. Acta Obst. Gynec. Jpn. 49; 195-198.
30. Murphy, D., Crowther, D., Renninson, J., Prendiville, J., Ranson, M., Lind, M., Patel, U., Dougal, M., Buckley, C. H. and Tindall, V. R. (1993) A randomized dose intensity study in ovarian carcinoma comparing chemotherapy given at 4-week intervals for 6 cycles with half dose chemotherapy given for 12 cycles. Ann. Oncol. 4; 377-383.
31. Ovarian Cancer Treatment Guidelines (Version 1) (2004) Japan Society of Gynecological Oncology, Kanehara-Shuppan.
32. Ozols, R. F. (1992) Chemotherapy for advanced epithelial ovarian cancer. Hematol. Oncol. Clin. North Am. 6; 879-894.
33. Ozols, R. F., Bundy, B. N., Greer, B. E., Fowley, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M. and Baergen, R. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 21; 3194-3200.
34. Ozols, R. F. (2004) Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. Cancer Invest. 22(Suppl 2); 11-20.
35. Piccart, M. J., Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G., Kaye, S., Vergote, I., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Trope, C., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. A., Lhoas, F., Lindvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Baron, B. and Pecorelli, S. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92; 699-708.
36. Shelling, A. N. (1997) Role of p53 in drug resistance in ovarian cancer. Lancet 349; 744-745.
37. Shinozuka, T., Miyamoto, T., Muramatsu, T., Hirasawa, T., Murakami, M., Makino, T. and Tanaka, Y. (1999) High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma. Cancer 85; 1555-1564.
38. Shinozuka, T., Muramatsu, T., Miyamoto, T., Hirasawa, T., Murakami, M., Makino, T., Sadahiro, S., Tanaka, Y. and Yasuda, M. (1999) Long-term results and prognostic analysis in advanced and recurrent/refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation. Int. J. Clin. Oncol. 4; 273-279.
39. Shpall, E. J., Clarke-Pearson, D., Soper, J. T., Berchuck, A., Jones, R. B., Bast, R. C., Ross, J. M., Lidor, Y., Vanacker, K., Tyler, T. and Peters, W. P. (1990) High dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol. Oncol. 38; 386-391.
40. Stiff, P., Bayer, R., Camarda, M., Tan, S., Dolan, J., Potkul, R., Loutfi, S., Kinch, L., Sosman, J., Peace, D., Rad, N. and McKenzie, R. S. (1995) A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol. Oncol. 57; 278-285.
41. Stiff, P. J., McKenzie, R. S., Alberts, D. S., Sosman, J. A., Dolan, J. R., Rad, N. and McCloskey, T. (1994) Phase I clinical and pharmacokinetic study of high dose mitoxantrone combined with carboplatin, cyclophosphamide and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J. Clin. Oncol. 12; 176-183.
42. Stiff, P. J., Bayer, R., Kerger, C., Patkul, R. K., Malhotra, D., Peace, D. J., Smith, D. and Fisher, S. G. (1997) High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J. Clin. Oncol. 15; 1309-1317.